Shield Therapeutics Plc

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc. (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies. Feraccru® is commercialized in the UK and European Union by Norgine B.V. (Norgine), which also has marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of Accrufer®/ Feraccru® in China, Hong Kong, Macau and Taiwan; with Korea Pharma Co., Ltd. for the Republic of Korea (Korea Pharma); and with KYE Pharmaceuticals Inc. for Canada.
Deal price

7.5p

Discount of

16.5%

Last Price 9p

Key information

Key information

Sector

Pharmaceuticals

Close date

Delivery

Placing price

Last price

Discount

Amount raised

7.5p

9 p

16.5 %

£1,500,000

Use of proceeds

The placing strengthens the Company's working capital position allowing the Board and management to focus completely on accelerating sales of ACCRUFeR®

Company announcement

https://www.londonstockexchange.com/news-article/STX/ps1-5-million-placing-supporting-growth-of-accrufer/17230020

Important notices

This website contains links to other websites and resources provided by third parties. These links are provided for your information only and we accept no responsibility for them or for any loss or damage that may arise from your use of them.

Investing in financial products involves taking risk. The value of investments can go up as well as down and you may receive back less than your original investment. CMC Markets UK plc trading as CMC CapX (“CMC”) does not provide investment advice of any kind and individual investors should make their own decisions or seek independent advice regarding the merits of entering into, and the suitability of, any investment. Nothing on this website and no communication from CMC should be construed as an investment recommendation. Only professional clients and eligible counterparties are eligible to participate in any offering in connection with CMC's services. There are inherent risks associated with investing in such offerings and such investments should only be made as part of a diversified portfolio. Nothing on this website constitutes an offer to sell, or a solicitation of an offer to buy, any security to any person in any jurisdiction to whom or in which such offer, solicitation or sale is unlawful.

Please read our Risk Warning before making any investment decisions.

Capx

Participate in exclusive deals

Start investing in exclusive deals.